In obese mice, FGF21 treatment has been shown to notably enhance insulin sensitivity, promote energy expenditure, and augment fat oxidation while also inhibiting de novo lipogenesis in the liver, thereby ameliorating obesity and its associated metabolic complications [36,37]. The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.